---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-019857"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T20:01:03.981268+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Achieve reports Q1 net loss $7.6M; positive Phase 3 ORCA-2 cytisinicline results

## Summary
- Net loss of $7.6M for Q1 2022; cash & equivalents $36.4M as of March 31, 2022.
- Phase 3 ORCA-2 cytisinicline met primary endpoints: 12-week abstinence 32.6% vs 7.0% placebo.
- Updated SVB debt facility provides remaining $10M available through April 2023.
- Appointed Dr. Vaughn Himes (CTO of Seagen) to Board of Directors in March 2022.
- Operating expenses $7.2M for Q1; shares outstanding 9,681,855 as of May 12, 2022.

## SEC filing metadata
- accession: 0001564590-22-019857
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000156459022019857/0001564590-22-019857-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000156459022019857/achv-8k_20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-019857
- JSON: https://secwatch.observer/filing/0001564590-22-019857.json
- Plain text: https://secwatch.observer/filing/0001564590-22-019857.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.